0001209191-20-042498.txt : 20200715
0001209191-20-042498.hdr.sgml : 20200715
20200715170011
ACCESSION NUMBER: 0001209191-20-042498
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200714
FILED AS OF DATE: 20200715
DATE AS OF CHANGE: 20200715
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hirsch David
CENTRAL INDEX KEY: 0001619884
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 201030014
MAIL ADDRESS:
STREET 1: C/O LONGITUDE CAPITAL PARTNERS, LLC
STREET 2: 800 EL CAMINO REAL, SUITE 220
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472846548
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-14
0
0001661460
Poseida Therapeutics, Inc.
PSTX
0001619884
Hirsch David
C/O POSEIDA THERAPEUTICS, INC.
9390 TOWNE CENTRE DRIVE, SUITE 200
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2020-07-14
4
C
0
2464245
A
2464245
I
See footnote
Common Stock
2020-07-14
4
P
0
250000
16.00
A
2714245
I
See footnote
Series B Preferred Stock
2020-07-14
4
C
0
2581755
D
Common Stock
2070373
0
I
See footnote
Series C Preferred Stock
2020-07-14
4
C
0
491159
D
Common Stock
393872
0
I
See footnote
Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
Represents shares held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power over securities held by LVP III. The reporting person is a member of LCP III and may be deemed to share voting, investment and dispositive power with respect to securities held by LVP III. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
/s/ Johanna M. Mylet, Attorney-in-Fact
2020-07-15